Evropská unie - španělština - EMA (European Medicines Agency)

mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agentes antineoplásicos - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

Evropská unie - španělština - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agentes antineoplásicos - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. para obtener más información sobre el estado del receptor 2 del factor de crecimiento epidérmico humano (her2), consulte la sección 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. para más información sobre el estado de her2, consulte la sección 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Uruguay - španělština - Ministerio de Salud (Dirección Oficina Central)

urufarma - solución inyectable - bevacizumab 100 mg/4 ml (25 mg/ml) inyectable

Uruguay - španělština - Ministerio de Salud (Dirección Oficina Central)

urufarma - solución inyectable - bevacizumab 400 mg/16 ml (25 mg/ml) inyectable

Peru - španělština - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

pharmaris peru s.a.c. - droguerÍa - bevacizumab - concentrado para solucion para perfusion - 400mg/16ml - por vial - - bevacizumab

Peru - španělština - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

pharmaris peru s.a.c. - droguerÍa - bevacizumab - concentrado para solucion para perfusion - 100mg/4ml - por vial - - bevacizumab

Ekvádor - španělština - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

mabxience research s.l. espaÑa - bevacizumab 25 mg/1 ml - concentrado para soluciÓn para perfusiÓn - cada vial de 1 ml contiene: bevacizumab 25,00 mg

Ekvádor - španělština - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

amgen technology (ireland) uc irlanda - cada ml de concentrado contiene 25mg de bevacizumab. - concentrado para solucion para perfusion - cada vial contiene 25 mg/ml de bevacizumab

Ekvádor - španělština - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

f.hoffmann-la roche s.a. [ch] switzerland - bevacizumab 25mg/ml 100mg/4ml 400mg/16ml - concentrado para soluciÓn para infusiÓn - cada vial de 4ml contiene: bevacizumab 100,0 mg cada vial de 16 ml contiene: bevacizumab 400,0 mg

Kuba - španělština - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

f. hoffmann-la roche sa, basilea suiza. - bevacizumab -